Genotoxic therapies were independent prognostic factors in IDH mutated grade II and grade III gliomas but lost significance in IDH mutated subgroups divided by the status of 1p/19q codeletion and TERT promoter mutations. This evidence concerns the gene IDH1 and glioma.